| Program | Indication | Research | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| ATYR1923 | Pulmonary Sarcoidosis |
|
||||
| Other ILDs (CTD-ILD; CHP)(1) |
|
|||||
| Healthy Japanese Volunteers(2) |
|
|||||
| COVID-19 related severe respiratory complications |
|
|||||
| ATYR2810 | Solid Tumors |
|
||||
| NRP2 mAbs | Cancer; Inflammation |
|
||||
| AARS-1; DARS‑1(3) | Cancer; Fibrosis; Inflammation |
|
||||
| Program | Target | Phase |
|---|---|---|
| ATYR1923 | Pulmonary Sarcoidosis | Phase 2 |
| Other ILDs (CTD-ILD; CHP)1 | Phase 1 | |
| Healthy Japanese Volunteers2 | Phase 1 | |
| COVID-19 related severe respiratory complications | Phase 3 | |
| ATYR2810 | Solid Tumors | Preclinical |
| NRP2 mAbs | Cancer; Inflammation | Research |
| AARS-1; DARS-1(3) | Cancer; Fibrosis; Inflammation | Research |
(1) CTD-ILD: connective tissue disease-related ILD (e.g. Scleroderma-related ILD); CHP: chronic hypersensitivity pneumonitis
(2) In partnership with Kyorin Pharmaceutical Co., Ltd.
(3) The next two candidates from our tRNA synthetase platform; initial focus on NK cell biology.